title: Osteoporotic vertebral fractures in a man under high-dose inhaled glucocorticoid therapy. A case-report with a review of the literature.
abstract: A 65-year-old man had surgery in June 1995 for femoral neuralgia. The plain films of the spine were normal at the time. In September of the same year, when he was beginning to walk gradually longer distances, he started experiencing back pain. Crush fractures of T8 and L2 were seen on plain films. His pain worsened, and he was admitted in December 1995. A third set of plain films disclosed fractures of all the vertebral bodies from T8 through L5, with increased density of the endplates of the same vertebras. Serum and urinary levels of calcium and phosphate were normal. Dual-energy X-ray absorptiometry demonstrated osteoporosis predominating in the trabecular bone. Evidence of increased bone resorption was seen on the histomorphometric study. Large amounts of dihydroxypyridinoline were found in the urine. Investigations for the classical causes of osteoporosis in males were unrewarding. Careful questioning revealed that the patient had been taking inhaled beclomethasone for seven years to treat chronic obstructive lung disease. Serum levels of cortisol and ACTH were low, consistent with a diagnosis of treatment-induced hypercorticism. To our knowledge, this is the first reported case of osteoporotic vertebral fractures in a male due to inhaled glucocorticoid therapy. Inhaled glucocorticoids are generally believed to induce only minimal systemic effects. However, decreased serum osteocalcin levels and increased urinary excretion of bone resorption markers have been reported in patients under inhaled beclomethasone therapy. Low spinal bone mineral density values correlated with the degree of pituitary-adrenal gland suppression as evaluated using the ACTH test have also been found in several groups of patients treated with inhaled glucocorticoids.
authors.affiliation: Rheumatology Department, Rangueil Teaching Hospital, Toulouse, France.
authors.forename: M
authors.initials: M
authors.lastname: Laroche
authors.forename: L
authors.initials: L
authors.lastname: Porteau
authors.forename: P
authors.initials: P
authors.lastname: Caron
authors.forename: L
authors.initials: L
authors.lastname: Moulinier
authors.forename: A
authors.initials: A
authors.lastname: Didier
authors.forename: J M
authors.initials: JM
authors.lastname: Amigues
authors.forename: A
authors.initials: A
authors.lastname: Cantagrel
authors.forename: B
authors.initials: B
authors.lastname: Mazieres
mesh_terms: D000280:Administration, Inhalation; D000287:Administration, Topical; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001507:Beclomethasone / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005938:Glucocorticoids; D006801:Humans; D008159:Lumbar Vertebrae / Q000293:injuries*; D008173:Lung Diseases, Obstructive / Q000188:drug therapy; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced* / Q000150:complications*; D011859:Radiography; D016103:Spinal Fractures / Q000000981:diagnostic imaging / Q000209:etiology*; D013904:Thoracic Vertebrae / Q000293:injuries*
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D001507:Beclomethasone